Preclinical efficacy of oral and nasal rivastigmine-loaded chitosan nano-particles on AlCl-induced Alzheimer's-like disease in rats.

The successful treatment of Alzheimer's disease (AD) is still a big challenge. Rivastigmine is one of the most used drugs for the treatment of AD. The short half-life, lower bioavailability, and less concentration of the drug in the brain after oral delivery are considered the main drawbacks of rivastigmine.